Infectious Diseases News and Research

RSS

Small pox virus destruction pushed back to 2014

The last existing vials of smallpox virus in the U.S. and Russia and due for destruction, have won at least another three years in existence. This is suggesting other countries concur with the U.S. about their value, one leading health official said. The experts and delegates at the annual meeting of the World Health Organization agreed on Tuesday to wait until 2014 to decide on a firm deadline for the final destruction of the lethal virus.

24 May 2011

HIV & hepatitis fears for soldiers at Middle East hospital due to protocol lapse

Australian soldiers and contractors might have been exposed to blood-borne diseases such as hepatitis or HIV after staff at Defense’s main hospital unit in the Middle East failed to sterilize surgical equipment properly.

24 May 2011

Accelerator announces Series A financing of Oncofactor

Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator.

24 May 2011

NIAID team completes analysis of most proteins produced by elephantiasis parasite worm

A team led by Thomas B. Nutman, M.D., of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has completed a large-scale analysis of most of the proteins produced by Brugia malayi, one kind of parasitic worm that causes lymphatic filariasis, or elephantiasis.

24 May 2011

Novel hepatitis C-like virus discovered in dogs

In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

Practical solutions for translational science from Randox Laboratories

The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering.

From Randox Laboratories Ltd. 23 May 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Lab21 acquires molecular diagnostics company Myconostica Ltd

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has today announced that it has acquired Myconostica Ltd, a molecular diagnostic company focussing on the diagnosis of fungal infections of clinical importance.

23 May 2011

Travel, hunting, and venison consumption linked to prion diseases

Researchers from the Centers for Disease Control and Prevention have examined the potential for human exposure to prion diseases, looking at hunting, venison consumption, and travel to areas in which prion diseases have been reported in animals.

23 May 2011

Walter and Eliza Hall Institute researcher selected Fellow of the Royal Society

Internationally recognised malaria researcher Professor Alan Cowman from the Walter and Eliza Hall Institute in Melbourne, Australia, has been elected a Fellow of the Royal Society, the UK's peak academy promoting excellence in science.

21 May 2011

First nucleic acid amplification test to diagnose early stages of Q fever infections receives FDA approval

The U.S. Food and Drug Administration today cleared the first nucleic acid amplification test to diagnose the early stages of Q fever infections in military personnel serving overseas.

21 May 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

New research shows that African Americans with systemic lupus erythematosus had a higher antibody response to influenza vaccination than European American patients.

21 May 2011

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

A technology that could allow cancer specialists to better determine the most effective chemotherapy treatment for a given patient won the $10,000 in first prize money in the 11th annual Big Bang! Business Plan Competition at the University of California, Davis. The contest is run by MBA students in the Graduate School of Management.

20 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

AIDS mortality in China drops by nearly two thirds since 2002 when country began free treatment program

China's HIV/AIDS-related mortality has dropped from 39.3 per 100 person-years in 2002 to 14.2 in 2009, or 64 percent, since the nation began providing free antiretroviral therapy (ART) in 2002, according to a study conducted by researchers from the Chinese Center for Disease Control and Prevention and published online Wednesday in Lancet Infectious Diseases, the New York Times reports (McNeil, 5/18).

20 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

People living with HIV/AIDS in China face discrimination when accessing health care, report says

HIV-positive people living in China "are routinely being denied medical treatment in mainstream hospitals due to fear and ignorance about the disease," according to a study based on interviews with 103 people living with HIV/AIDS and 23 health care workers that was conducted by the International Labor Organization and China's National Center for STD and AIDS Prevention and Control, Reuters reports.

19 May 2011

Infectious Diseases News and Research

Small pox virus destruction pushed back to 2014

HIV & hepatitis fears for soldiers at Middle East hospital due to protocol lapse

Accelerator announces Series A financing of Oncofactor

NIAID team completes analysis of most proteins produced by elephantiasis parasite worm

Novel hepatitis C-like virus discovered in dogs

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Practical solutions for translational science from Randox Laboratories

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Lab21 acquires molecular diagnostics company Myconostica Ltd

Travel, hunting, and venison consumption linked to prion diseases

Walter and Eliza Hall Institute researcher selected Fellow of the Royal Society

First nucleic acid amplification test to diagnose early stages of Q fever infections receives FDA approval

African Americans with SLE have higher antibody response to influenza vaccination: Study

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

AIDS mortality in China drops by nearly two thirds since 2002 when country began free treatment program

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

People living with HIV/AIDS in China face discrimination when accessing health care, report says

Industry Focus eBook - Infectious Diseases (3rd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News